These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1299 related items for PubMed ID: 19363453

  • 1. Anakinra for systemic juvenile arthritis: the Rocky Mountain experience.
    Zeft A, Hollister R, LaFleur B, Sampath P, Soep J, McNally B, Kunkel G, Schlesinger M, Bohnsack J.
    J Clin Rheumatol; 2009 Jun; 15(4):161-4. PubMed ID: 19363453
    [Abstract] [Full Text] [Related]

  • 2. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France.
    Lequerré T, Quartier P, Rosellini D, Alaoui F, De Bandt M, Mejjad O, Kone-Paut I, Michel M, Dernis E, Khellaf M, Limal N, Job-Deslandre C, Fautrel B, Le Loët X, Sibilia J, Société Francophone pour la Rhumatologie et les Maladies Inflammatoires en Pédiatrie (SOFREMIP), Club Rhumatismes et Inflammation (CRI).
    Ann Rheum Dis; 2008 Mar; 67(3):302-8. PubMed ID: 17947302
    [Abstract] [Full Text] [Related]

  • 3. Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis.
    Verbsky JW, White AJ.
    J Rheumatol; 2004 Oct; 31(10):2071-5. PubMed ID: 15468378
    [Abstract] [Full Text] [Related]

  • 4. Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome.
    Neven B, Marvillet I, Terrada C, Ferster A, Boddaert N, Couloignier V, Pinto G, Pagnier A, Bodemer C, Bodaghi B, Tardieu M, Prieur AM, Quartier P.
    Arthritis Rheum; 2010 Jan; 62(1):258-67. PubMed ID: 20039428
    [Abstract] [Full Text] [Related]

  • 5. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series.
    Nigrovic PA, Mannion M, Prince FH, Zeft A, Rabinovich CE, van Rossum MA, Cortis E, Pardeo M, Miettunen PM, Janow G, Birmingham J, Eggebeen A, Janssen E, Shulman AI, Son MB, Hong S, Jones K, Ilowite NT, Cron RQ, Higgins GC.
    Arthritis Rheum; 2011 Feb; 63(2):545-55. PubMed ID: 21280009
    [Abstract] [Full Text] [Related]

  • 6. High dose, alternate day corticosteroids for systemic onset juvenile rheumatoid arthritis.
    Kimura Y, Fieldston E, Devries-Vandervlugt B, Li S, Imundo L.
    J Rheumatol; 2000 Aug; 27(8):2018-24. PubMed ID: 10955346
    [Abstract] [Full Text] [Related]

  • 7. The efficacy and safety of interleukin-1-receptor antagonist anakinra in the treatment of systemic juvenile idiopathic arthritis.
    Swart JF, Barug D, Möhlmann M, Wulffraat NM.
    Expert Opin Biol Ther; 2010 Dec; 10(12):1743-52. PubMed ID: 20979564
    [Abstract] [Full Text] [Related]

  • 8. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate.
    Cohen SB, Moreland LW, Cush JJ, Greenwald MW, Block S, Shergy WJ, Hanrahan PS, Kraishi MM, Patel A, Sun G, Bear MB, 990145 Study Group.
    Ann Rheum Dis; 2004 Sep; 63(9):1062-8. PubMed ID: 15082469
    [Abstract] [Full Text] [Related]

  • 9. Anakinra treatment for systemic onset juvenile idiopathic arthritis (SOJIA).
    Ohlsson V, Baildam E, Foster H, Jandial S, Pain C, Strike H, Ramanan AV.
    Rheumatology (Oxford); 2008 Apr; 47(4):555-6. PubMed ID: 18321945
    [No Abstract] [Full Text] [Related]

  • 10. Patient- versus physician-reported outcomes in rheumatoid arthritis patients treated with recombinant interleukin-1 receptor antagonist (anakinra) therapy.
    Cohen SB, Strand V, Aguilar D, Ofman JJ.
    Rheumatology (Oxford); 2004 Jun; 43(6):704-11. PubMed ID: 14997006
    [Abstract] [Full Text] [Related]

  • 11. Anakinra: review of recombinant human interleukin-I receptor antagonist in the treatment of rheumatoid arthritis.
    Furst DE.
    Clin Ther; 2004 Dec; 26(12):1960-75. PubMed ID: 15823761
    [Abstract] [Full Text] [Related]

  • 12. Concomitant medication use in a large, international, multicenter, placebo controlled trial of anakinra, a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis.
    Tesser J, Fleischmann R, Dore R, Bennett R, Solinger A, Joh T, Modafferi D, Schechtman J, 990757 Study Group.
    J Rheumatol; 2004 Apr; 31(4):649-54. PubMed ID: 15088288
    [Abstract] [Full Text] [Related]

  • 13. Effect of anakinra on functional status in patients with active rheumatoid arthritis receiving concomitant therapy with traditional disease modifying antirheumatic drugs: evidence from the OMEGA Trial.
    Le Loët X, Nordström D, Rodriguez M, Rubbert A, Sarzi-Puttini P, Wouters JM, Woolley JM, Wright N, Lawrence C, Appleton B.
    J Rheumatol; 2008 Aug; 35(8):1538-44. PubMed ID: 18634163
    [Abstract] [Full Text] [Related]

  • 14. Rapid and sustained remission of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome through treatment with anakinra and corticosteroids.
    Bruck N, Suttorp M, Kabus M, Heubner G, Gahr M, Pessler F.
    J Clin Rheumatol; 2011 Jan; 17(1):23-7. PubMed ID: 21169853
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type.
    Quartier P, Taupin P, Bourdeaut F, Lemelle I, Pillet P, Bost M, Sibilia J, Koné-Paut I, Gandon-Laloum S, LeBideau M, Bader-Meunier B, Mouy R, Debré M, Landais P, Prieur AM.
    Arthritis Rheum; 2003 Apr; 48(4):1093-101. PubMed ID: 12687553
    [Abstract] [Full Text] [Related]

  • 16. Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis.
    Ostendorf B, Iking-Konert C, Kurz K, Jung G, Sander O, Schneider M.
    Ann Rheum Dis; 2005 Apr; 64(4):630-3. PubMed ID: 15345502
    [Abstract] [Full Text] [Related]

  • 17. Rapid responses to anakinra in patients with refractory adult-onset Still's disease.
    Fitzgerald AA, Leclercq SA, Yan A, Homik JE, Dinarello CA.
    Arthritis Rheum; 2005 Jun; 52(6):1794-803. PubMed ID: 15934079
    [Abstract] [Full Text] [Related]

  • 18. Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis.
    Woo P, Southwood TR, Prieur AM, Doré CJ, Grainger J, David J, Ryder C, Hasson N, Hall A, Lemelle I.
    Arthritis Rheum; 2000 Aug; 43(8):1849-57. PubMed ID: 10943876
    [Abstract] [Full Text] [Related]

  • 19. A case of macrophage activation syndrome successfully treated with anakinra.
    Kelly A, Ramanan AV.
    Nat Clin Pract Rheumatol; 2008 Nov; 4(11):615-20. PubMed ID: 18825135
    [Abstract] [Full Text] [Related]

  • 20. Anakinra treatment for systemic juvenile idiopathic arthritis and adult onset Still disease.
    Woo P.
    Ann Rheum Dis; 2008 Mar; 67(3):281-2. PubMed ID: 18292104
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 65.